NCT01527500 - Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) | Biotech Hunter

Enrollment

158

Participants

Timeline

Start Date

January 25, 2012

Primary Completion Date

June 24, 2015

Study Completion Date

June 24, 2015

Conditions

Geographic AtrophyAge-related Macular Degeneration

Interventions

DRUG

LFG316

LFG316 5 mg/50 μL solution for IVT injection,

DRUG

Sham

Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)

DRUG

LFG316 Lower dose

LFG316 5 mg/50 μL solution for IVT Injection

Trial Locations (19)

28210

Novartis Investigative Site, Charlotte

30342

Novartis Investigative Site, Atlanta

33143

Novartis Investigative Site, Miami

33880

Novartis Investigative Site, Winter Haven

44122

Novartis Investigative Site, Cleveland

45242

Novartis Investigative Site, Cincinnati

49202

Novartis Investigative Site, Jackson

49546

Novartis Investigative Site, Grand Rapids

66211

Novartis Investigative Site, Leawood

80909

Novartis Investigative Site, Colorado Springs

85014

Novartis Investigative Site, Phoenix

85020

Novartis Investigative Site, Phoenix

90211

Novartis Investigative Site, Beverly Hills

95841

Novartis Investigative Site, Sacramento

98383

Novartis Investigative Site, Silverdale

85704-5614

Novartis Investigative Site, Tucson

91105-3153

Novartis Investigative Site, Pasadena

33912-7125

Novartis Investigative Site, Fort Myers

02114

Novartis Investigative Site, Boston